BioAge Labs, Inc. (BIOA) Dividend History

BioAge Labs, Inc. is a biotechnology company focused on developing therapies to target aging and age-related diseases. Leveraging insights from aging biology, it aims to extend healthspan and improve quality of life by identifying and modulating molecular pathways involved in aging processes.

Dividend History

BioAge Labs, Inc. currently does not pay dividends

Company News

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

BioAge Labs initiated a Phase 1 clinical trial for BGE-102, an oral small molecule NLRP3 inhibitor targeting obesity treatment, with potential to address neuroinflammation and complement existing therapies like GLP-1 agonists.

GlobeNewswire Inc.
BioAge Labs (BIOA) Q2 Revenue Hits $2.4M

BioAge Labs reported Q2 2025 earnings with first collaboration revenue of $2.41 million, increased R&D expenses, and continued development of obesity and metabolic disease treatments, including BGE-102 and APJ agonist programs.

The Motley Fool
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of the Concurrent Private Placement

BioAge Labs, a clinical-stage biopharmaceutical company, announced the closing of its initial public offering and concurrent private placement, raising approximately $238.3 million in gross proceeds.

Benzinga

Page data last updated 08/19/2025 16:56:35 UTC